⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399930 | 0.81 | — | — | |
| SCHEMBL12836105 | 0.80 | — | — | |
| SCHEMBL5040815 | 0.78 | HSP90AA1 (0.37) | — | |
| SCHEMBL1012306 | 0.75 | — | — | |
| SCHEMBL650452 | 0.75 | — | — | |
| SCHEMBL244702 | 0.75 | — | — | |
| SCHEMBL31351780 | 0.75 | — | — | |
| SCHEMBL250764 | 0.75 | — | — | |
| SCHEMBL11364572 | 0.75 | — | — | |
| SCHEMBL19597662 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-110003384-B | Polymer, preparation method and application thereof | 东莞东阳光医疗智能器件研发有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-8889676-B2 | 3-ureidoisoquinolin-8-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-06 | — | — | US | disclosed |
| EP-2691373-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-02-05 | — | — | EP | disclosed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | disclosed |
| EP-1451161-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | Merck Sharp & Dohme Limited (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048132-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |